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Introduction:  Delirium is an acute and fluctuating disturbance of 
consciousness and cognition, that occurs in the majority of critically ill patients. It is 
hence associated with several diseases of severity and infection. As critically ill 
patients are subjected to numerous risk factors for delirium such as sedative, analgesic 
agents and pre-existing systemic illness, some of these may be modified to reduce the 
risk factors for delirium.  
 
Objectives:  The aim of the study was to determine the association between 
serum concentration of brain derived neurotrophic factor (BDNF) and Tau protein 
levels with delirium in mechanically ventilated ICU patients. Specific objectives 
included were 1) to compare the mean of length of stay (days)  in ICU between the 
delirious and non-delirious mechanically ventilated patients in ICU, 2) to compare the 
duration of mechanical ventilator usage (in days) between the delirious and non-
delirious patients in ICU, and 3) to determine whether different age group is a factor 
that influences the level of BDNF and Tau Proteins among delirium patients. 
 
Patients and Methods: This study was conducted in three phases: 1) the 
blood sampling within 12 hours and 48 hours of ICU admission, with subsequent 
centrifugation and storage of frozen plasma for the final testing using ELISA assay 
later, 2) the clinical diagnosis of delirium using the Confusion-Assessment Method in 
ICU (CAM-ICU), 3) a cross-sectional prospective study of 45 ICU patients to 
determine the associations between the blood levels of biomarkers which are Brain-
derived Neurotrophic Factors and Tau protein with delirious patients who are 
mechanically ventilated in ICU (HUSM)  
 
Results: The median BDNF levels were significantly lower in the delirium 
patients when compared to the non-delirium patients within the first day of admission, 
(71.22ng/mL, IqR 33.78 vs 103.76ng/mL IqR 41.91), p-value of 0.001. There was no 
significant difference in the median BDNF levels after 48 hours (day 3) from ICU 
admission between the delirious and non-delirious group, (8.69ng/mL, IqR 10.70 vs 
12.16, IqR 10.79), respectively, with a p-value of 0.573. The median levels of Tau 
protein on day 1 and day 3, were not statistically significant for either the delirious 
and the non-delirious group, with day 1 ICU admission having Tau protein levels of 
0.18ng/mL, IqR 0.12 vs 0.16ng/mL, IqR 0.10, and with day 3 ICU admission having 
delirum Tau protein levels of 84.66ng/mL, IqR 122.23 vs non-delirium Tau protein 
levels 55.48 ng/mL, IqR 30.9. The results show that there were significant differences 
in the median length of stay between delirium and non-delirium groups, 11(7) and 
5(6) respectively, with p-value of 0.003. The length of delirium patients requiring 
mechanical ventilator (in days) were significantly longer compared to the non-
delirium patients, 9(7) and 3(5) respectively. In total, it was found that there were 
more ventilated patients in ICU having delirium at 57.5% (n=23) compared to 42.5% 
(n=17) for non-delirium patients. Median age of patients in ICU was 45 years old 
accounting 7.5% of all patients. Subsequent division of age range into three groups 
were done, with younger age from 18 to 35 years old, median age from 36 to 55 years 
old and older age from 56 to 65 years old. Out of 40 patients, 30%(n=12) were at the 
younger age group, 32.5% (n=13) were at median age group and 37.5% (n=15) were 
at the older age group. Among them, it was found that 57.5% (n=23) were delirious 
and 42.5% (n=17) were non-delirious. 34.78% (n=8) from the delirious group were at 
younger age, 26.1% (n=6) were at median age and 39.1% (n=9) were at older age. 
Further results show that among the 17 non-delirious patients, 23.5% (n=4) were at 
younger age, 41.8% (n=7) were at median age and 35.3% (n=6) were at older age.  
 
Conclusion: This study demonstrates that there was an association between 
ICU admission levels of BDNF and the occurrence of delirium in ICU patients, in the 
pathophysiology of ICU delirium, suggesting a role for neuronal death occurring in 
the pre-ICU delirium setting or soon after admission of within 12 hours, and not 
during the ICU stay. However, Tau protein levels do not correlate with the occurrence 
of delirium in ICU HUSM. 
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ABSTRAK 
 
Tajuk: Hubungkait Antara Paras Protin Brain-Derived Neurotrophic Factor Dan 
Protin Tau Bagi Pesakit-pesakit Unit Rawatan Rapi Yang Mengalami Kecelaruan 
 
Latarbelakang dan objektif: 
Kecelaruan, iaitu suatu gangguan kesedaran dan kognitif yang akut dan turun naik, 
sering berlaku kepada pesakit-pesakit yang kritikal dan  berlaku sehingga 80% daripada 
pesakit yang kritikal. Dengan itu, ia dikaitkan dengan beberapa tahap penyakit dan 
jangkitan. Oleh kerana pesakit-pesakit kritikal adalah terdedah kepada banyak faktor-
faktor risiko untuk kecelaruan seperti ubat penenang, agen analgesik dan penyakit-
penyakit sistemik yang sedia ada, sesetengah daripadanya boleh diubahsuai untuk 
mengurangkan risiko kecelaruan. Kajian ini adalah untuk menghubungkaitkan paras 
darah untuk Brain-derived neurotrophic factors dan Protin Tau dengan pesakit-pesakit 
yang mengalami kecelaruan semasa diberi bantuan pernafasan mekanikal di Unit 
Rawatan Rapi HUSM. 
 
Metodologi: 
Ini adalah kajian prospektif keratan rentas (cross section)yang telah dijalankan di Unit 
Rawatan Rapi HUSM daripada bulan Jun 2013 sehingga November 2013. Sebanyak 45 
orang pesakit unit rawatan rapi tidak kira samada mengalami kecelaruan atau tidak 
telah terlibat didalam kajian ini. Di dalam tempoh 12 jam daripada waktu kemasukan 
unit rawatan rapi, darah telah diambil untuk analisa penanda bio-asas dan 48 jam 
seterusnya, satu lagi sampel darah telah diambil. Kecelaruan telah didiagnosa dengan 
menggunakan kaedah Confusion-Assessment Method in ICU (CAM-ICU). Asai ELISA 
 ix  
untuk plasma Protin Tau dan BDNF telah dilakukan untuk mendapatkan paras darah 
untuk penanda bio. Untuk mendapatkan hubungkaitan di antara paras darah penanda-
bio iaitu Brain-derived neurotrophic factors dan Protin Tau dengan pesakit yang 
mengalami kecelaruan, analisa non-parametric telah dilaksanakan. 
 
Keputusan: 
Seramai 45 pesakit-pesakit telah dipilih untuk kajian ini, tetapi 5 daripada mereka telah 
digugurkan kerana CAM-ICU tidak dapat dilaksanakan ke atas mereka disebabkan 
pelalian yang mendalam dengan skor RASS di antara -4 ke -5. Sehingga ke akhir  
tempoh berada di Unit Rawatan Rapi, semua subjek yang digugurkan telah meninggal 
dunia. Pesakit-pesakit diantara umur 18 hingga 65 tahun secara dermografik telah 
dipilih untuk menyertai kajian ini. Didapati median untuk paras darah BDNF bagi 
mereka yang mengalami kecelaruan adalah rendah secara signifikannya, berbanding 
dengan pesakit yang tidak mengalami kecelaruan pada hari pertama kemasukan ke Unit 
Rawatan Rapi, (71.22ng/mL, IqR 33.78 vs. 103.76ng/mL, IqR 41.91) dengan nilai-p 
bersamaan 0.001. Didapati, tiada perbezaan secara signifikan di antara pesakit yang 
mengalami kecelaruan dengan yang tidak mengalami kecelaruan bagi median paras 
darah BDNF) setelah kemasukan ke Unit Rawatan Rapi 48 jam kemudian, iaitu 
masing-masing dengan median BDNF (8.69ng/mL, IqR 10.70 vs.12.16, IqR 
10.79),nilai-p=0.573. Manakala,  bagi median paras darah Protin Tau pada hari pertama 
kemasukan dan seterusnya hari kedua selepas kemasukan ke Unit Rawatan Rapi, tiada 
langsung hubungkaitan di antara paras darah Protin Tau untuk pesakit yang mengalami 
kecelaruan dengan yang tidak mengalami kecelaruan, dengan paras darah Protin Tau 
pada hari pertama kemasukan ke Unit Rawatan Rapi adalah 0.18ng/mL, IqR 0.12 vs. 
0.16ng/mL, IqR 0.10, dan paras darah Protin Tau pada hari kedua selepas kemasukan 
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ke Unit Rawatan Rapi untuk pesakit yang mengalami kecelaruan adalah 84.66ng/mL, 
IqR 122.23 vs. 55.48ng/mL, IqR 30.95 untuk pesakit yang tidak mengalami kecelaruan, 
dengan nilai-p>0.005. 
 
Umur median bagi pesakit-pesakit di Unit Rawatan Rapi adalah 45 tahun iaitu 7.5% 
daripada jumlah keseluruhan pesakit. Seterusnya, pembahagian lingkungan umur 
kepada 3 kumpulan telah dilakukan, dengan kumpulan usia muda di antara 18 hingga 
35 tahun, kumpulan usia pertengahan di antara 36 hingga 55 tahun dan kumpulan usia 
lanjut di antara 56 ke 65 tahun. Daripada 40 pesakit, 30%(n=12) adalah kumpulan 
muda, 32.5% (n=13) adalah daripada usia pertengahan dan 37.5% (n=15) adalah 
daripada kumpulan usia lanjut. Daripada jumlah keseluruhan kumpulan tersebut, 
didapati 57.5% (n=23) telah mengalami kecelaruan dan 42.5% (n=17) adalah yang 
tidak mengalami kecelaruan. 34.78% (n=8) daripada kumpulan yang mengalami 
kecelaruan pula terdiri daripada kumpulan usia muda, 26.1% (n=6) adalah daripada 
kumpulan usia pertengahan dan 39.1% (n=9) terdiri daripada kumpulan berusia lanjut. 
Keputusan yang diperolehi juga menunjukkan perbezaan yang ketara (signifikan) pada 
median jangkamasa berada di Unit Rawatan Rapi di antara kumpulan yang mengalami 
kecelaruan dengan yang tidak mengalami kecelaruan, iaitu masing-masing 11(7)hari 
dan 5(6) hari, dengan nilai p=0.003. Jangkamasa pesakit yang mengalami kecelaruan 
bergantung kepada mesin bantuan pernafasan (jumlah hari) adalah lebih lama 
berbanding dengan mereka yang tidak mengalami kecelaruan, iaitu masing-masing 9 
(7) hari dan 3(5) hari, dengan nilai-p=0.002. Secara keseluruhannya, didapati lebih 
ramai pesakit yang diberi bantuan pernafasan mekanikal di Unit Rawatan Rapi untuk 
mengalami kecelaruan iaitu 57.5% (n=23) berbanding dengan 42.5% (n=17) pesakit 
yang tidak mengalami kecelaruan, dengan nilai-p=0.002. 
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Konklusi: 
Kajian ini menunjukkan bahawa terdapatnya hubungkaitan di antara paras darah BDNF 
dengan kejadian pesakit mengalami kecelaruan semasa kemasukan ke Unit Rawatan 
Rapi. Ini menunjukkan bahawa kecelaruan yang dialami mungkin telah berlaku 
sebelum kemasukan pesakit ke Unit Rawatan Rapi, dan mencadangkan peranan 
kematian neuron-neuron yang mungkin telah berlaku sebelum kemasukan atau sejurus 
selepas kemasukan ke Unit Rawatan Rapi dalam tempoh 12 jam terawal, dan bukannya 
sepanjang tempoh pesakit berada di Unit Rawatan Rapi. Walaubagaimanapun, paras 
darah Protin Tau didapati tiada berhubungkait dengan kejadian pesakit mengalami 
kecelaruan di Unit Rawatan Rapi. 
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ABSTRACT 
 
Title: Association of Brain-Derived Neurotropic Factors and Tau Protein Blood 
Levels with Delirium Patients in Intensive Care Unit 
 
Background: 
Delirium, an acute and fluctuating disturbance of consciousness and cognition, 
frequently occurs in critically ill patients, occurring up to 80% of the critically ill. It is 
hence associated with several disease severity and infection. As critically ill patients are 
subjected to numerous risk factors for delirium such as sedative, analgesic agents and 
pre-existing systemic illness, some of these may be modified to reduce the risk factors 
for delirium. The aim of the study was to determine the association between serum 
concentration of brain derived neurotrophic factor (BDNF) and Tau protein levels with 
delirium in mechanically ventilated ICU patients.  
 
Methodology: 
This was a prospective cross-sectional study from June 2013 until November 2013 
done in ICU HUSM. 45 ICU patients with or without delirium were included. Within 
12 hours of ICU admission, blood was obtained for baseline biomarker analysis and 
subsequently 48 hours later, another blood sample was obtained. Delirium was 
diagnosed by using the Confusion-Assessment Method in ICU (CAM-ICU). ELISA 
assay for the plasma Tau protein and BDNF were performed to obtain the blood level 
for these biomarkers. To determine the associations between the blood levels of 
biomarkers which are Brain-derived Neurotrophic Factors and Tau protein with 
 xiii  
delirious patients who are mechanically ventilated in ICU (HUSM), non-parametric 
analysis were performed.  
 
Results: 
45 patients were included into this study but 5 were dropped out due to inability to 
perform CAM-ICU as a result of deep sedation with RASS score ranging from -4 to -5. 
Until the end of their stay, all drop outs died in ICU. Demographically, patients from 
the age 18 to 65 years old were included. We found that the median BDNF levels were 
significantly lower in the delirium patients when compared to the non-delirium patients 
within the first day of admission, (71.22ng/mL, IqR 33.78 vs 103.76ng/mL IqR 41.91) 
with p-value of 0.001. There was no significant difference in the median BDNF levels 
after 48 hours (day 3) from ICU admission between the delirious and non-delirious 
group, (8.69ng/mL, IqR 10.70 vs 12.16, IqR 10.79), respectively, with a p-value of 
0.573.However, for the median of Tau protein on day 1 and day 3, the levels were not 
statistically significant for either the delirious and the non-delirious group, with day 1 
ICU admission having Tau protein levels of 0.18ng/mL, IqR 0.12 vs 0.16ng/mL, IqR 
0.10, and with day 3 ICU admission having delirum Tau protein levels of 84.66ng/mL, 
IqR 122.23 vs non-delirium Tau protein levels 55.48 ng/mL, IqR 30.95, with p-value > 
0.005. 
 
Median age of patients in ICU was 45 years old accounting 7.5% of all patients. 
Subsequent division of age range into three groups were done, with younger age from 
18 to 35 years old, median age from 36 to 55 years old and older age from 56 to 65 
years old. Out of 40 patients, 30%(n=12) were at the younger age group, 32.5% (n=13) 
were at median age group and 37.5% (n=15) were at the older age group. Among them, 
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it was found that 57.5% (n=23) were delirious and 42.5% (n=17) were non-delirious. 
34.78% (n=8) from the delirious group were at younger age, 26.1% (n=6) were at 
median age and 39.1% (n=9) were at older age. Further results show that among 17 
non-delirious patients, 23.5% (n=4) were at younger age, 41.8% (n=7) were at median 
age and 35.3% (n=6) were at older age. The results show that there were significant 
differences in the median length of stay between delirium and non-delirium groups, 
11(7) and 5(6) respectively, with p-value of 0.003.The length of delirium patients 
requiring mechanical ventilator (in days) were significantly longer compared to the 
non-delirium patients, 9(7) and 3(5) respectively, with a p-value of 0.002. 
In total, it was found that there were more ventilated patients in ICU having delirium at 
57.5% (n=23) compared to 42.5% (n=17) for non-delirium patients. 
 
Conclusion: 
This study demonstrates that there was an association between ICU admission levels of 
BDNF and the occurrence of delirium in ICU patients, in the pathophysiology of ICU 
delirium, suggesting a role for neuronal death occurring in the pre-ICU delirium setting 
or soon after admission of within 12 hours, and not during the ICU stay. However, Tau 
protein levels do not correlate with the occurrence of delirium in ICU. 
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CHAPTER ONE 
INTRODUCTION  
1.1. Background 
Delirium is defined as an acute change or fluctuation in mental status, 
inattention, and disorganised thinking or an altered level of consciousness. 
Delirium is a common manifestation of acute brain dysfunction in mechanically 
ventilated patients in ICU and can occur up to 60-80% of mechanically 
ventilated ICU patients (Gunther et al 2008). Various factors were identified for 
delirium such as metabolic disturbances, extreme old age, baseline cognitive 
impairment, sepsis, hypoxaemia, sleep disturbances, medications such as 
anticholinergics, sedatives and analgesic medications of opioid based. 
 
The diagnosis of delirium can be primarily tested clinically and is based on 
meticulous bedside observation of key features with two-step process. First of 
all, the level of arousal is measured and if patient is arousable, CAM-ICU is 
used for delirium detection. CAM-ICU is an abbreviation for the Confusion 
Assessment Method for the Intensive Care Unit, which was designed and 
validated in concert with long-standing delirium experts in Geriatrics and 
Neuropsychology such as Dr. Sharon Inouye, Dr. Joseph Francis, and Dr. 
Robert Hart in 2001. (www.icudelirium.org/docs). CAM-ICU is an excellent 
diagnostic tool in critically ill ICU patients to assess delirium. It is a clinical 
evaluation for delirium, which involves linking sedation and delirium 
monitoring using a two-step approach to assess consciousness (Refer Figure 
2.1 Linking RASS and CAM-ICU in a two-step assessment).  
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Apart from clinical evaluation for delirium, biomarkers such as Tau Protein and 
Brain-derived Neurotrophic Factor (BDNF) levels can be correlated with 
clinical findings in ICU.  Neurotrophin is a neurotrophic factor whereas 
neurotrophic factor is a form of neuropeptides that act as nerve growth factor 
that regulates the growth, differentiation, and survival of certain neurons in the 
peripheral and central nervous systems (www.merriam-webster.com). 
Therefore, BDNF is a form of neuropeptides derived from the brain that act as 
nerve growth factor that regulates the growth, differentiation and survival of 
certain neurons.  Tau Protein on the other hand is a protein that binds to and 
regulates the assembly and stability of neuronal microtubules and that is found 
in an abnormal form as the major component of neurofibrillary tangles 
(www.merriam-webster.com). Tau Proteins are implemented in clinical trials to 
reflect biological activity, mechanisms of action of compounds, support 
enrichment of target populations, provide endpoints for proof-of-concept and 
confirmatory trials on disease modification. (Hampel et al 2010). Tau represents 
the subunit protein of one of the major hallmarks of Alzheimer disease (AD), 
the neurofibrillary tangles, and is therefore of major interest as an indicator of 
disease mechanism. (EM Mandelkow et al 2012).  
 
BDNF has long been known to be critical for the growth and survival of 
neurons and Tau Protein. It has a direct corelationship with the severity of 
dementia, which suggests that BDNF and pathological Tau Proteins are reliable 
marker of the neurodegenerative process, possibly including delirium. (Buée et 
al 2000; Gunther et al 2008). The recent discovery of tau gene mutations in 
fronto-temporal dementia with parkinsonism linked to chromosome 17 (FTDP-
 17  
17) has reinforced the predominant role attributed to Tau Proteins in the 
pathogenesis of neurodegenerative disorders, and underlined the fact that 
distinct sets of tau isoforms expressed in different neuronal populations could 
lead to different pathologies. (Buée et al 2000). 
 
However, for identification of delirium, risk factors of delirium need to be 
identified and routine laboratory tests such as full blood count (FBC), arterial 
blood gas (ABG), serum electrolytes, blood urea nitrogen (BUN), urine drug 
screens, liver function tests (LFT), glucose level, ECG, CXR and blood cultures 
are also important. 
 
Since delirium has been poorly diagnosed due to the misleading understanding 
of delirium, the condition is often unrecognised due to many clinicians 
attributing delirium symptoms to dementia or depression.  
 
Given that delirium is the most commonly occurring in the critically ill patients 
in ICU up to 20-80%, depending on the severity of the illnesses, hence, it is 
important to diagnose and manage this dysfunction by implementation of 
validated screening tools and pharmacological treatment.  
 
We hope by conducting this study, detection of delirium can be improved and 
help to reduce morbidity and mortality as delirium is associated with poor short-
term outcomes and may result in adverse sequelae years after ICU discharge. 
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1.2. Rationale of the study  
Given that the incidence of delirium in the critically ill patients is the most 
common incidence occurring in ICU of up to 20-80%, depending on the 
severity of the illnesses and its association with consequential worse acute and 
chronic sequelae, it is therefore important to diagnose and manage this 
dysfunction by implementation of validated screening tools and 
pharmacological treatment (Gunther et al 2008). 
 
The reason that Tau protein and Brain-Derived Neurotrophic Factors were 
selected for the determination of delirium from plasma is that both biomarkers 
can be correlated with clinical findings in ICU. 
 
The most commonly used sandwich ELISA kit shows a good specificity (90%) 
and sensitivity (81%), discriminating Alzheimer’s disease and controls (S 
Schaer-Marschke et al 2008). Therefore, this study is reproducible at any time 
for the detection of delirium, as delirium is a part of acute brain dysfunction that 
somehow mimic neurodegenerative diseases such as Alzheimer’s disease. 
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1.3. Objectives of the study 
1.3.1.   General objective: 
To determine the correlation of the blood level of Tau protein and 
BDNF with patients having delirium in ICU. 
 
1.3.2.  Specific objectives: 
a. To compare the mean blood levels of Tau protein and BDNF 
between the delirious and non-delirious mechanically ventilated 
patients in ICU. 
b. To compare the mean of length of stay(days)  in ICU between the 
delirious and non-delirious mechanically ventilated patients in ICU. 
c. To compare the duration of mechanical ventilator usage (in days) 
between the delirious and non-delirious patients in ICU. 
d. To determine whether different age group is a factor that influences 
the level of BDNF and Tau Proteins among delirium patients. 
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CHAPTER TWO 
LITERATURE REVIEW  
2.1. Delirium 
2.1.1.  Definition 
Delirium is an acute change in mental status marked by a fluctuating course of 
impaired attention, disorganised thinking, and disturbance of consciousness. In 
the American Psychiatric Association’s (APA) Diagnostic and Statistical 
Manual of Mental Disorders (DSM-IV), delirium is defined as a disturbance of 
consciousness and cognition that develops over a short period of time (hours to 
days) and fluctuates over time.  
 
Historically, a myriad of terms such as acute confusional state, ICU psychosis, 
ICU syndrome, acute brain dysfunction and encephalopathy have been used to 
describe delirium. The word ‘delirium’ was first used as a medical term as 
early as the first century AD to describe mental disorders occurring during 
fever or head trauma (Chadwick J.1950). Delirium is used as a standard term 
for a diverse range of conditions, including acute confusional state, acute brain 
syndrome, acute cerebral insufficiency and toxic–metabolic encephalopathy. 
Over time, the term delirium has evolved to describe a transient, reversible 
syndrome that is acute and fluctuating, and which occurs in the setting of a 
medical condition (Fong et al 2009). 
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However, nowadays the critical care literature has started to conform to the 
recommendations of experts and the APA that the term delirium to be used 
uniformly to describe this brain dysfunction syndrome. A lot of times delirium 
is under diagnosed and have been poorly documented in the intensive care 
settings due to the perception that patients who are critically ill in ICU are well 
sedated and comfortable. Furthermore, delirium is often unrecognised by 
clinicians or incorrectly attributed to depression, dementia or considered as an 
expected, inconsequential complication of critical illness. Given that delirium 
is the most common organ dysfunction to be found in critically ill patients in 
ICU and is associated with consequential worse acute and chronic sequelae, 
hence, it is important to diagnose and manage this disease by implementation 
of validated screening tools.  
 
2.1.2.  Prevalence and subtypes 
The prevalence rates of delirium can be as high as 60-80% based on the reports 
in medical and surgical ICU cohort studies. (Gunther et al 2008). This 
observation was made depending upon the severity of illness and the diagnostic 
methods used. There are two different pathways that exist in inflamed and non-
inflamed Intensive Care Unit patients who are found to be delirious. Lipowskiin 
1983 described a more useful clinical category that can be categorised into 
subtypes according to psychomotor behaviour as follows: 
a. Hypoactive delirium 
b. Hyperactive delirium 
c. Mixed delirium 
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The characteristics for hypoactive delirium includes decreased physical and 
mental inattention, decreased responsiveness, appear more withdrawn and 
apathic. Patients in ICU may be sluggish and lethargic, stuporous and may be 
associated with a worse prognosis. This high prevalence of hypoactive delirium 
in critically ill patients probably contributes to clinician’s lack of recognition of 
delirium. 
 
For hyperactive delirium, it is characterised by agitation, restlessness, 
combativeness and emotional liability. Manifestations of hyperactive delirium 
include groping or picking at the bedclothes or attempting to get out of bed at 
an inappropriate time which could cause harm and untimely damage to patients 
(Girard et al 2008). This exposes both patients and caregivers at risk for serious 
injuries.  However, this form of delirium occurs only in the minority of 
critically ill patients. A cohort study done by Peterson and coworkers observed 
that purely hyperactive delirium was rare of 1.6%, whereas 43.5% of patients in 
ICU had hypoactive delirium and 54.1% had mixed delirium. Among non-ICU 
patients, hyperactive delirium has been associated with a better prognosis than 
hypoactive delirium, but it has not been evaluated thoroughly among ICU 
patients (Girard et al 2008). 
 
2.1.3.  Diagnosis of delirium in ICU 
Despite that patients when admitted to the ICU are mechanically ventilated, 
sedated and critically ill, delirium can be assessed by linking sedation and 
delirium monitoring using a two-step approach to assess consciousness, as 
shown in the diagram below.  
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Figure 2.1 Linking RASS and CAM-ICU in a two-step assessment 
 
Step One: Sedation assessment 
The Richmond Agitation and Sedation Scale: The RASS* 
Score Term Description  
+4 Combative Overtly combative, violent, 
immediate danger to staff  
+3 Very agitated Pulls or removes tube(s) or 
catheter(s); aggressive  
+2 Agitated Frequent non-purposeful 
movement, fights ventilator  
+1 Restless Anxious but movement not 
aggressive vigorous  
0 Alert and calm   
-1 Drowsy Not fully alert but has sustained 
awakening (eye opening/eye 
contact) to voice (≥ 10 seconds) 
 
-2 Light sedation Briefly awakens with eye contact 
to voice (<10 seconds) 
-3 Moderate 
sedation 
Movement or eye opening to voice 
(but no eye contact) 
-4 Deep sedation No response to voice but 
movement or eye opening to 
physical stimulation 
 -5 Unarousable No response to voice or physical 
stimulation 
 
 
 
Procedure for RASS Assessment 
 
1. Observe patient. 
a. Patient is alert, restless or agitated        (score 0 to +4) 
 
2. If not alert, state patient’s name and say to open eyes and look at speaker. 
a. Patient awakens with sustained eye opening and eye contact. (score -1) 
b. Patient awakens with eye opening and eye contact but not sustained
 (score -2) 
c. Patient has any movement in response to voice but no eye contact (score -3) 
 
Verbal Stimulation 
Physical 
Stimulation 
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3. When no response to verbal stimulation, physically stimulate patient by shaking 
shoulder and/or rubbing sternum. 
 
 
a. Patient has any movement to physical stimulation    (score -4) 
b. Patient has no response to any stimulation    (score -5) 
 
If RASS is -4 or -5, then Stop and Reassess patient at a later time. 
If RASS is above -4 (-3 through +4) the Proceed to Step 2. 
 
*Sessler, et al. AJRCCM 2002; 166:1338-1334. Ely, et al. JAMA 2003; 289:2983-2991 
 
 
Step Two: Delirium Assessment 
 
 
 
 
 
 
  
 
 
 
 
  
Feature 1: Acute onset of mental status changes or a fluctuating course 
Feature 2: Inattention 
Feature 3: Disorganized Thinking Feature 4: Altered Level of Consciousness 
And 
And 
OR 
= DELIRIUM 
